TRAIL has profound anti-MM activity following interaction with death receptor-4 and -5 (149–151), whereas IL-2 can contribute to antitumor immunity by stimulating cytotoxic CD8-positive T cells and NK cells in the tumor microenvironment (167, 168). This evidence concerns the gene TNFSF10 and Miyoshi myopathy.